Biomira Announces Final Phase 2b Survival Results of Stimuvax®

28 April 2006 Filed under Uncategorized Posted by admin » No Comments


Biomira Announces Final Phase 2b Survival Results of Stimuvax® (formerly known as BLP25 Liposome Vaccine) Trial in Patients With Non-Small Cell Lung Cancer

Results Confirm Median Survical of 30.6 Months in Stage IIIB Patients on Vaccine Versus 13.3 Months in Control Patients

Share and Enjoy:
  • Digg
  • del.icio.us
  • ThisNext
  • Furl
  • Facebook
  • Google Bookmarks
  • MySpace
  • Twitter
  • Yahoo! Bookmarks
  • Yahoo! Buzz
  • email
  • MSN Reporter

Trackback URL

No Comments

You must be logged in to post a comment.